Welcome to our dedicated page for Motus GI Holdings news (Ticker: $MOTS), a resource for investors and traders seeking the latest updates and insights on Motus GI Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Motus GI Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Motus GI Holdings's position in the market.
Motus GI Holdings, a medical technology company, reported its Q1 2024 financial results and corporate updates. The U.S. launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system doubled the number of active customers, with 100% adopting the system independently. The company appointed an investment bank to explore strategic alternatives to boost commercialization and stockholder value. Revenues for Q1 2024 increased to $64,000 from $56,000 in Q1 2023, primarily from disposable sleeve reorders. Despite this, the net loss deepened to $7.6 million from $4.4 million year-over-year. Cash and equivalents stood at $4.9 million as of March 31, 2024.